Berg Daniel, Otley Clark C
Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA.
J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20. doi: 10.1067/mjd.2002.125579.
In the United States more than 100,000 people are living with solid organ transplants. The intense immunosuppressive regimens necessary for prolonged survival of allografts significantly increase the rates of both internal and cutaneous malignancies in recipients of solid organ transplants. Skin cancer is the most common cancer in patients after transplantation. Because of the early onset and high tumor burden in transplant recipients, dermatologists have significant challenges in managing the treatment of these patients. This article describes the epidemiology and clinical presentation of skin cancer during posttransplantation immunosuppression, discusses pathogenic cofactors, and reviews the optimal management for mild and severe skin cancer in transplant recipients.
在美国,超过10万人接受了实体器官移植。为使同种异体移植物长期存活而必须采用的强化免疫抑制方案,显著增加了实体器官移植受者发生内脏恶性肿瘤和皮肤恶性肿瘤的几率。皮肤癌是移植患者中最常见的癌症。由于移植受者发病早且肿瘤负荷高,皮肤科医生在管理这些患者的治疗方面面临重大挑战。本文描述了移植后免疫抑制期间皮肤癌的流行病学和临床表现,讨论了致病辅助因素,并综述了移植受者轻度和重度皮肤癌的最佳管理方法。